AMRX
Price
$10.56
Change
+$0.17 (+1.64%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
3.26B
24 days until earnings call
ZTS
Price
$145.39
Change
-$1.03 (-0.70%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
64.89B
29 days until earnings call
Interact to see
Advertisement

AMRX vs ZTS

Header iconAMRX vs ZTS Comparison
Open Charts AMRX vs ZTSBanner chart's image
Amneal Pharmaceuticals
Price$10.56
Change+$0.17 (+1.64%)
Volume$16.63K
Capitalization3.26B
ZOETIS
Price$145.39
Change-$1.03 (-0.70%)
Volume$16.65K
Capitalization64.89B
AMRX vs ZTS Comparison Chart in %
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. ZTS commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a StrongBuy and ZTS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (AMRX: $10.39 vs. ZTS: $146.42)
Brand notoriety: AMRX: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 108% vs. ZTS: 87%
Market capitalization -- AMRX: $3.26B vs. ZTS: $64.89B
AMRX [@Pharmaceuticals: Generic] is valued at $3.26B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $64.89B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.89B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, AMRX is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while ZTS’s TA Score has 5 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 4 bearish.
  • ZTS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both AMRX and ZTS are a good buy in the short-term.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а +6.56% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +2.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.37%. For the same industry, the average monthly price growth was +5.95%, and the average quarterly price growth was +58.35%.

Reported Earning Dates

AMRX is expected to report earnings on Oct 30, 2025.

ZTS is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.37% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($64.9B) has a higher market cap than AMRX($3.26B). AMRX has higher P/E ratio than ZTS: AMRX (1040.00) vs ZTS (25.21). AMRX YTD gains are higher at: 31.187 vs. ZTS (-9.255). ZTS has higher annual earnings (EBITDA): 4.02B vs. AMRX (584M). ZTS has more cash in the bank: 1.44B vs. AMRX (71.5M). AMRX has less debt than ZTS: AMRX (2.58B) vs ZTS (6.79B). ZTS has higher revenues than AMRX: ZTS (9.39B) vs AMRX (2.85B).
AMRXZTSAMRX / ZTS
Capitalization3.26B64.9B5%
EBITDA584M4.02B15%
Gain YTD31.187-9.255-337%
P/E Ratio1040.0025.214,125%
Revenue2.85B9.39B30%
Total Cash71.5M1.44B5%
Total Debt2.58B6.79B38%
FUNDAMENTALS RATINGS
AMRX vs ZTS: Fundamental Ratings
AMRX
ZTS
OUTLOOK RATING
1..100
8862
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
41100
SMR RATING
1..100
9919
PRICE GROWTH RATING
1..100
4363
P/E GROWTH RATING
1..100
2384
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZTS's Valuation (34) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew somewhat faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that AMRX’s stock grew somewhat faster than ZTS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew significantly faster than AMRX’s over the last 12 months.

AMRX's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as ZTS (63) in the Pharmaceuticals Generic industry. This means that AMRX’s stock grew similarly to ZTS’s over the last 12 months.

AMRX's P/E Growth Rating (23) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (84) in the Pharmaceuticals Generic industry. This means that AMRX’s stock grew somewhat faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXZTS
RSI
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
67%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
55%
MACD
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
60%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 6 days ago
57%
Declines
ODDS (%)
Bearish Trend 12 days ago
75%
Bearish Trend 4 days ago
57%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
64%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPYD44.280.29
+0.66%
SPDR® Portfolio S&P 500® High Div ETF
DIAX14.780.01
+0.07%
Nuveen DOW 30Sm Dynamic Overwrite Fund
EYEG36.22N/A
N/A
AB Corporate Bond ETF
APOC25.95N/A
-0.02%
Innovator Eq Dfnd Prt ETF - 6 Mo Apr/Oct
AESR20.59-0.07
-0.34%
Anfield US Equity Sector Rotation ETF

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with PAHC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
-0.10%
PAHC - AMRX
45%
Loosely correlated
-1.77%
VTRS - AMRX
45%
Loosely correlated
+0.79%
TEVA - AMRX
41%
Loosely correlated
-0.20%
COLL - AMRX
39%
Loosely correlated
+0.96%
ZTS - AMRX
38%
Loosely correlated
-0.05%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-0.05%
ELAN - ZTS
48%
Loosely correlated
+0.83%
VTRS - ZTS
48%
Loosely correlated
+0.79%
PAHC - ZTS
42%
Loosely correlated
-1.77%
HLN - ZTS
39%
Loosely correlated
+0.79%
AMRX - ZTS
38%
Loosely correlated
-0.10%
More